Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer | Zendy

David Cunningham | Zendy; Yves Humblet | Zendy; Salvatore Siena | Zendy; David Khayat | Zendy; Harry Bleiberg | Zendy; Armando Santoro | Zendy; D. Bets | Zendy; M. Mueser | Zendy; A. Harstrick | Zendy; Chris Verslype | Zendy; Ian Chau | Zendy; Eric Van Cutsem | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Author(s) -

David Cunningham,

Yves Humblet,

Salvatore Siena,

David Khayat,

Harry Bleiberg,

Armando Santoro,

D. Bets,

M. Mueser,

A. Harstrick,

Chris Verslype,

Ian Chau,

Eric Van Cutsem

Publication year - 2004

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa033025

Subject(s) - cetuximab , irinotecan , medicine , colorectal cancer , oncology , regimen , combination therapy , cancer

The epidermal growth factor receptor (EGFR), which participates in signaling pathways that are deregulated in cancer cells, commonly appears on colorectal-cancer cells. Cetuximab is a monoclonal antibody that specifically blocks the EGFR. We compared the efficacy of cetuximab in combination with irinotecan with that of cetuximab alone in metastatic colorectal cancer that was refractory to treatment with irinotecan.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research